Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: JOEBT1 who wrote (22693)	6/25/1998 11:44:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Joebt1, I would not interpret the CTCL data as indicating that Targretin oral would not have utility there. CTCL is a fatal disease and the side effects of high dose treatment are reversible and treatable. The problems with CTCL do not appear to present in other malignancies very often (frequency is 1.6%). When I get a chance, I'll translate the abstracts. In general, they show that LGND has many compounds that are superior to the FDA approved "gold standard" for each area. The improvement is either better efficacy or fewer side effects. The markets being targeted are huge and the pre-clinical data is promising (and LGND has many back-up candidates).